Expanded Access Programs List

The FDA allows cancer patients to access investigational treatments outside an ongoing clinical trial through a program called Expanded Access. Colloquially, this is often referred to as Compassionate Use. Investigational treatments are unapproved medicines, which are currently in clinical trials. The Expanded Access program is defined and authorized under 21C FR part 312 subpart I.

To participate, patients must be*:

  • in advanced stage, terminal disease;
  • out of treatment options; and
  • unable to access an existing clinical trial.

*Paraphrased for the sake of brevity. Full criteria are included in the website links provided below

The FDA’s Expanded Access program includes a significant number of gating criteria. Assuming a patient qualifies, a physician must make a request for access to an investigational treatment, and the company (sponsor) that owns the treatment must agree to the use of their investigational drug. If this happens, and all other basic qualifications are met, the FDA grants 99% of requests that it receives.

If you are a cancer patient who does not qualify for a clinical trial and meets the criteria above, you should speak to your physician about potentially accessing a promising new therapy through expanded access. Request to companies and the FDA must be made by a licensed physician. Each company has its own criteria for evaluating and granting Expanded Access requests. Notably, factors unrelated to the patient may limit access, such as insufficient clinical grade drug.

To assist cancer patients and physicians, CytImmune has compiled a list of pharmaceutical company websites and contact information through which physicians may begin the application process for Expanded Use.

 

Website Physician Contact/ Request Forms Timeline
Novartis Program Information Website/Form
Roche Program Information Website/Form
Cellgene Program Information Website/Form
J&J Program Information U.S.: 1-800-Janssen or janssenmedinfo@its.jnj.com
BMS Program Information Website/Form 48 hours
Lilly Program Information US: 1-800-LillyRx (1-800-545-5979) 5 Days
Takeda Program Information Not Listed
AstraZeneca Program Information US: 1-800-236-9933
Merck & Co. Program Information 1-800-672-6372
Amgen Program Information 1 800-772-6436
Pfizer Program Information <href=”http://www.cybergrants.com/pfizercares/docs/PfizerCAReS_physician_submission_job_aid.pdf”>Application Instructions
Astellas Program Information US: 800-727-7003
Bayer Program Information 1-888-842-2937
Otsuka Program Information ExpandedAccess@otsuka-us.com
Sanofi Program Information Form on Program Info website
Eisai Program Information 1-888-274-2378 2 days
Abbvie Program Information Website/Form

**CytImmune’s nanomedicine products cannot currently be accessed through the FDA’s Expanded Access program. Once our first and second generation clinical products are in an active clinical trial, we will post information regarding our Expanded Access policies and procedures.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.